

BREAST

CHELSEA HOTEL, TORONTO, ON
ROOM: MOUNTBATTEN SALON
SATURDAY APRIL 29, 2023, 8:00 AM – 12:00 PM

BREAST DISEASE SITE GENERAL MEETING

CO-CHAIRS : S.CHIA / E. RAKOVITCH
SENIOR INVESTIGATORS: L. SHEPHERD / W. PARULEKAR

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- Identify and address, through clinical trial and translational research, the disease burden associated with breast cancer in Canada.
- Identify clinical trial research opportunities within the Canadian Cancer Trials Group.
- Integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct.
- Apply best practices in clinical trials conduct and analysis to the Canadian Cancer Trials Group research agenda.
- To provide a learning and mentoring environment supportive to new investigators.
- To synthesize, disseminate, exchange and apply knowledge derived from clinical trials to improve the health of Canadians.

8:00am	Welcome & Review of Morning's Objectives (Feedback, Recognition of centres with high accrual)
8:10am	Update: Publications/Abstracts 2022-2023
8:25am	Update from the IND Committee
8:50am	Approved Studies Pending Activation
9:15am	Studies Open to Accrual
10:15am	Coffee
10:30am	News from Closed/Analyzed Studies
11:00am	Barriers to trial Activation Focus on MA.39
11:15am	Brainstorming for new trial proposals – awareness of process
11:30am	Summary of 2023APR27 Retreat / Potential New Studies
11:50am	Other Business
12:00pm	Adjournment



Appendix I – Agenda Details

Objectives

CCTG Presentations for ASCO / 2022/2023 Publications

Update from the IND Committee (Phil Bedard to introduce)

Open Trials:

- **IND.241** - A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Studies Open to Accrual

- **MA.39 - Tailor RT:** A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (**T. Whelan**)
- **MAC.22 / TMIST** - ECOG-ACRIN EA1151 Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (**M. Yaffe**)
- **MAC.26 (S1706)** - A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (**E. Rakovitch**)
- **MAC.27 / A011801** - COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib (**P. Blanchette**)
- **MAC.28 / NRG BR007** - A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score \leq 18 Breast Cancer (DEBRA) (**V. Theberge**)
- **PM.1 (CAPTUR)** - Canadian Profiling and Targeted agent Utilization trial (CAPTUR) a Phase II Basket Trial (**L. Shepherd**)
- **MA.41 (Decrescendo)** - De-Escalation of adjuvant ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 bLOckade (DECRESCENDO) (**P. Bedard**)

News from Closed to Accrual Studies put up a slide listing non-highlighted studies.

- **MA.32R A Late Recurrence Substudy of A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early-Stage Breast Cancer**
- **MAC18 (A221405)- POSITIVE:** A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy (**L.Shepherd/E. Warner**) – 10-15 minutes
- **MAC.19 (A011202)** - A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy (**S. Latosinsky**)
- **MAC.20 (A011401)** - Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (**V. Bernstein**)
- **MAC.21 (A011502)** - Aspirin for Breast Cancer (ABC): Randomized Trial of Aspirin as Adjuvant Therapy for Node Positive Breast Cancer (**M. Salim**)
- **MAC .23 (A221505):** A Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (**I. Kong**)
- **MAC.24 (SWOG 1418)** - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (pN1) After Neoadjuvant Chemotherapy (**S.Chia**)
- **MAC.25 (NRG-BR1751)** - Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Cancer (**S.Chia**)

Other Business



List of Publications 2022-2023

Breast Publications 1 January 2022 – 6 April 2023

Publications

1. Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TT, Muanza TM, Neal A, Olivetto IA: Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. *The Lancet* 2022; 400(10350):431-440.
Keywords: BRE/MA33/Phase 3/Primary
Notes: Recd fr CDavidson; primary confirmed CDavidson; entered COshea 2023FEB07
2. Connolly RM, Miller KD: Back to the Beginning: The Role of Ovarian Suppression in Management of Hormone Sensitive Breast Cancer in Premenopausal Women. *J Clin Oncol* 2023; 41(7):1339-1341.
Keywords: BRE/MAC4/MAC5
Notes: Recd fr CWinch; entered COshea 2023MAR26; abstract NA
3. Delahanty LM, Wadden TA, Goodwin PJ, Alfano CM, Thomson CA, Irwin ML, Neuhouser ML, Crane TE, Frank E, Spears PA, Gillis BP, Hershman DL, Paskett ED, Hopkins J, Bernstein V, Stearns V, White J, Hudis C, Winer EP, Carey A, Partridge AH, Ligibel JA: The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. *Obesity* 2022; 30(1):28-38.
Keywords: BRE/Intergroup Other Lead/MAC20
Notes: Recd fr HStanton; entered COshea 2022NOV01
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Braybrooke J, Gray R, Hills RK, Liu Z, Pan H, Peto R, Dodwell D, McGale P, Taylor C, Francis PA, Gnant M, Perrone F, Regan MM, Berry R, Boddington C, Clarke M, Davies C, Davies L, Duane F, Evans V, Gay J, Gettins L, Godwin J, James S, Liu H, MacKinnon E, Mannu G, McHugh T, Morris P, Read S, Straiton E, Jakesz R, Fesl C, Pagani O, Gelber R, De Laurentiis M, De Placido S, Gallo C, Albain K, Anderson S, Arriagada R, Bartlett J, Bergsten-Nordström E, Bliss J, Brain E, Carey L, Coleman R, Cuzick J, Davidson N, Del Mastro L, Di Leo A, Dignam J, Dowsett M, Ejlertsen B, Goetz M, Goodwin P, Halpin-Murphy P, Hayes D, Hill C, Jaggi R, Janni W, Loibl S, Mamounas EP, Martijn M, Mukai H, Nekjudova V, Norton L, Ohashi Y, Pierce L, Poortmans P, Pritchard KI, Raina V, Rea D, Robertson J, Rutgers E, Spanic T, Sparano J, Steger G, Tang G, Toi M, Tutt A, Viale G, Wang X, Whelan T, Wilcken N, Wolmark N, Cameron D, Bergh J, Swain SM: Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. *The Lancet Oncology* 2022; 23(3):382-392.
Keywords: BRE/MAC4/MAC5/secondary analysis
Notes: Recd fr HStanton; entered COshea 2022JAN09
5. Francis PA, Fleming GF, Láng I, Ciruelos EM, Bonnefoi HR, Bellet M, Bernardo A, Climent MA, Martino S, Bermejo B, Burstein HJ, Davidson NE, Geyer CE, Walley BA, Ingle JN, Coleman RE, Müller B, Le Du F, Loibl S, Winer EP, Ruepp B, Loi S, Colleoni M, Coates AS, Gelber RD, Goldhirsch A, Regan MM: Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. *J Clin Oncol* 2023; 41(7):1370-1375.
Keywords: BRE/MAC4/MAC5
Notes: Recd fr CWinch; entered COshea 2023MAR26
6. Garcia SF, Gray RJ, Sparano JA, Tevaarwerk AJ, Carlos RC, Yanez B, Gareen IF, Whelan TJ, Sledge GW, Cella D, Wagner LI: Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. *Cancer* 2022; 128(3):536-546.
Keywords: BRE/Intergroup Other Lead/MAC12/secondary analysis
Notes: Recd fr HStanton; entered COshea 2022JAN05
7. Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff AC, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga JM, Rubovsky G, Bliss JM, Mayer IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Hernando Fernández de Aránguiz B, Haddad TC, Perelló A, Bellet M, Fohler H, Metzger Filho O, Jallitsch-Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl C, DeMichele A, Mayer EL: Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). *J Clin Oncol* 2022; 40(3):282-293.
Keywords: BRE/Intergroup Other Lead/MA37/Primary
Notes: Recd fr HStanton; Primary confirmed by LShepherd; entered by COshea 2021DEC10; updated COshea 2022FEB01
8. Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ, Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ, Bliss JM, Rastogi P, Rabaglio-Poretti M, Mukherjee SD, Mackey JR, Abramson VG, Oja C, Wesolowski R, Thompson AM, Rea DW, Stos PM, Shepherd LE, Stambolic V, Parulekar WR: Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial. *J Am Med Assoc* 2022; 327(20):1963-1973.
Keywords: BRE/CTG Lead/MA32/Primary
Notes: Recd fr LCallahan; primary confirmed by WParulekar; entered COshea 2022MAY25
9. Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, Wagner LI, Sledge GW: Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). *J Clin Oncol* 2022; 40(9):978-987.



Keywords: BRE/Intergroup Other Lead/MAC14/Primary

Notes: Recd fr HStanton; primary confirmed by LShepherd 2022JAN19; entered COshea 2022JAN20

10. Li Y, Zheng X, Tu D, Ingle JN, Goss PE, Parulekar WR, Qin G: Predicting the clinical outcomes and benefit from letrozole after 5-áyears of treatment with aromatase inhibitors for early breast cancer: analysis from CCTG MA.17R. *Breast Cancer Res Treat* 2022; 191(3):523-533.
Keywords: BRE/MA17r
Notes: Recd fr HStanton; entered COshea 2022JAN05; updated 2022APR28
11. Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown LC, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller B, Jochum W, Bonnefoi H, Martino S, Davidson NE, Geyer C, Chia SK, Ingle JN, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates AS, Goldhirsch A, Fleming GF, Francis PA, Speed TP, Regan MM, Loi S: Genomic characterisation of hormone receptor-positive breast cancer arising in very young women (**ONLINE**). *Ann Oncol* 2023.
Keywords: BRE/MAC4
Notes: recd fr CWinch; entered COshea 2023MAR27
12. Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, DeMichele A: Treatment Exposure and Discontinuation in the PALbociclib CoLaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). *J Clin Oncol* 2022; 40(5):449-458.
Keywords: BRE/Intergroup Other Lead/MA37/secondary analysis
Notes: Recd fr HStanton; entered COshea 2022JAN20
13. Pagani O, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Chini C, Puglisi F, Spazzapan S, Ruhstaller T, Winer EP, Ruepp B, Loi S, Coates AS, Gelber RD, Goldhirsch A, Regan MM, Francis PA: Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. *J Clin Oncol* 2023; 41(7):1376-1382.
Keywords: BRE/Intergroup Other Lead/MAC4/MAC5
Notes: Recd fr HStanton; entered COshea 2023JAN05
14. Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A: Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial (**ONLINE**). *J Clin Oncol* 2023.
Keywords: BRE/correlative science/Intergroup Other Lead/MA9/secondary analysis
Notes: Recd fr HStanton; entered COshea 2023JAN19

Abstracts

1. Abdou Y, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SK, Dhesy-Thind S, Rastogi P, Alba E, Delalogue S, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Unger JM, Tripathy D, Pusztai L, Hortobagyi GN, Kalinsky K. Race and clinical outcomes in the RxPONDER Trial (SWOG S1007). *Cancer Research* 83[5_Supplement], GS1-01. 3-1-2023. 12-6-2022.
Keywords: BRE/MAC15/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; oral presentation, 2022DEC06, SABCS, San Antonio, December 6-10, 2022; no pdf
2. Chen CSC, Zirpoli G, McCann S, Barlow WE, Budd GT, Pusztai L, Hortobagyi GN, Godwin AK, Thompson AM, Ambrosone CB, Stringer KA, Hertz DL. Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221. *Journal of Clinical Oncology* 40[16_suppl], 12023. 6-1-2022. Wolters Kluwer. 6-9-2022.
Keywords: BRE/MAC11
Notes: Recd fr HStanton; poster presentation at ASCO, June 3-7, 2022, Chicago, IL; entered COshea 2022JUN09
3. Chen Y, Barlow WE, Li H, Lu C, Janowczyk A, Corredor G, Ganesan S, Feldman M, Fu P, Gilmore H, Albain KS, Pusztai L, Rae J, Hayes D, Godwin AK, Thompson AM, Madabhushi A. Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H & E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from SWOG S8814. *Cancer Research* 83[5_Supplement], 2-11. 3-1-2023. 12-7-2022.
Keywords: BRE/MA9/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; poster presentation, 2022DEC07, SABCS, San Antonio, December 6-10, 2022; no pdf
4. Chia SK, Cescon DW, Redfern AD, Rodin D, Simmons C, Ayoub JP, Chalchal HI, Rayson D, Rushton-Marovac M, Hay T, Gallinaro L, Chen B, Parulekar W. CCTG MA40: Double-blind placebo controlled phase III trial of fulvestrant and ipatasertib for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer post first line CDK 4/6 and aromatase inhibitor therapy (FINER). *Cancer Research* 83[5_Supplement], OT3-26. 3-1-2023. 12-8-2022.
Keywords: BRE/MA40/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; poster presentation, 2022 DEC08, SABCS, San Antonio, December 6-10, 2022; no pdf



Canadian Cancer Society
Société canadienne du cancer

CCTG is a CCS national program.

5. DeMichele A, Dueck AC, Hlauschek D, Martin M, Burstein HJ, Pfeiler G, Zdenkowski N, Wolff AC, Balic M, Miller K, Cameron DA, Balko JM, Traina TA, Czajkowska D, Metzger O, Lu DR, O'Brien P, Fesl C, Mayer EL, Gnant M. Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort. *Journal of Clinical Oncology* 40[36_suppl], 390216. 10-20-2022. Wolters Kluwer. 10-18-2022.
Keywords: ASCO/BRE/Intergroup Other Lead/MA37
Notes: Recd fr LCallahan & HStanton; entered COshea 2022NOV07; oral presentation, October 18, 2022 at ASCO Monthly Plenary Series, online
6. Hershman DL, Chen BE, Parulekar WR, Lemieux J, Ligibel JA, Gelmon KA, Whelan TJ, Goodwin PJ. Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin versus placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32). *Journal of Clinical Oncology* 40[16_suppl], 526. 6-1-2022. Wolters Kluwer. 6-9-2022.
Keywords: BRE/MA32
Notes: Recd fr HStanton; poster presentation at ASCO, June 3-7, 2022, Chicago, IL; entered COshea 2022JUN09
7. Janni W, Untch M, Harbeck N, Gilgorov J, Jacot W, Chia SK, Boileau JF, Haftchenary S, Gupta R, Mishra N, Pathak P, Curigliano G. Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis. *Cancer Research* 83[5_Supplement], 1-02. 3-1-2023. 12-6-2022.
Keywords: BRE/general review/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; poster presentation, 2022DEC06, SABCS, San Antonio, December 6-10, 2022; no pdf
8. Kang I, Forschmiedt JK, Loch MM, Barlow WE, Lew DL, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Miao J, Tripathy D, Puzstai L, Hortobagyi GN, Kalinsky K, Henry NL. Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status. *Cancer Research* 83[5_Supplement], GS1-04. 3-1-2023. 12-6-2022.
Keywords: BRE/MAC15/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; oral presentation, 2022DEC06, SABCS, San Antonio, December 6-10, 2022; no pdf
9. Loch MM, Forschmiedt JK, Kang IM, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Rastogi P, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Barlow WE, Tripathy D, Puzstai L, Hortobagyi GN, Kalinsky K, Henry NL. Patient-reported anxiety and fatigue in women enrolled in the RxPONDER trial (SWOG S1007) by menopausal status. *Cancer Research* 83[5_Supplement], 6-05. 3-1-2023. 12-9-2022.
Keywords: BRE/MAC15/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; poster presentation, 2022DEC09, SABCS, San Antonio, December 6-10, 2022; no pdf
10. McCartney A, Biagioni C, Chen B, Shepherd L, Gelmon K, Joy AA, Parulekar W, Bergqvist M, Migliaccio I, Leo A, Benelli M, Risi E, Moretti E, Livraghi L, Biganzoli L, Malorni L. Serum thymidine kinase activity as a prognostic marker in women with metastatic breast cancer treated with two different schedules of palbociclib plus second-line endocrine therapy within the CCTG MA38 trial. *Cancer Research* 83[5_Supplement], 5-02. 3-1-2023. 12-8-2022.
Keywords: BRE/MA38/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; poster presentation, 2022DEC08, SABCS, San Antonio, December 6-10, 2022; no pdf
11. Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, hacek-Link J, Schurmans C, Theall KP, Fesl C, Dueck AC, DeMichele A, Gnant M. Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial. *Journal of Clinical Oncology* 40[16_suppl], 518. 6-1-2022. Wolters Kluwer. 6-1-2022.
Keywords: BRE/MA37
Notes: Recd fr HStanton; poster presentation, ASCO, June 3-7, 2022, Chicago, IL; entered COshea 2022JUN09
12. Pisano E, Gatsonis C, Schnall MD, Yaffe M, Troester MA, Gareen IF, Collins LC, Curtis A, Cole EB, Cormack J, Steingrimsson J, Carlos RC, Miller K, Comstock C. Adjusting the TMIST study design to accommodate slower than expected accrual: ECOG-ACRIN EA1151. *Journal of Clinical Oncology* 40[16_suppl], TPS10614. 6-1-2022. Wolters Kluwer. 6-9-2022.
Keywords: BRE/MAC22
Notes: Recd fr HStanton; poster presentation at ASCO, June 3-7, 2022, Chicago, IL; entered COshea 2022JUN09
13. Riaz N, Chen B, Bane A, Gao D, Stovgaard E, Kos Z, Leung S, Shenasa E, Parulekar W, Chambers S, Nielson T, Whelan TJ. Prognostic and Predictive Capacity of Tumor Infiltrating Lymphocytes in the MA.20 regional radiotherapy trial. *Cancer Research* 83[5_Supplement], 4-02. 3-1-2023. 12-8-2022.
Keywords: BRE/MA20/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; poster presentation, 2022DEC08, SABCS, San Antonio, December 6-10, 2022; no pdf
14. Shao D, Barlow WE, Li H, Lu C, Albain KS, Rae J, Hayes DF, Godwin AK, Thompson AM, Madabhushi A, Puzstai L. Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Study. *Cancer Research* 83[5_Supplement], 2-11. 3-1-2023. 12-7-2022.
Keywords: BRE/MA9/SABCS



Notes: Recd fr HStanton; entered COshea 2023MAR26; poster presentation 2022DEC07, SABCS, San Antonio, December 6-10, 2022; no pdf

15. Sparano J, Gray RJ, Makower D, Albain KS, Hayes DF, Geyer C, Dees E, Goetz MP, Olson JA, Jr., Lively TG, Badve S, Saphner T, Wagner LI, Whelan T, Kaklamani V, Sledge G. Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates. *Cancer Research* 83[5_Supplement], GS1-05. 3-1-2023. 12-6-2022.
Keywords: BRE/MAC12/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; oral presentation 2022DEC06, SABCS, San Antonio, December 6-10, 2022; no pdf
16. Spring LM, Barlow WE, Bardia A, Sharma P, Puzstai L, Hortobagyi GN, Kalinsky K. HER2-19 Impact of HER2 low status on clinical outcomes in participants with 1-3 positive lymph nodes, HR+/HER2- breast cancer with recurrence score \leq 25 randomized to endocrine therapy +/- chemotherapy: results from SWOG S1007 (RxPONDER). *Cancer Research* 83[5_Supplement], HER2-19. 3-1-2023. 12-7-2022.
Keywords: BRE/MAC15/SABCS
Notes: Recd fr HStanton; entered COshea 2023MAR26; poster session, 2022DEC07, SABCS, San Antonio, December 6-10, 2022; no pdf
17. White JR, Anderson SJ, Harris EE, Mamounas EP, Stover DG, Ganz PA, Jaggi R, Cecchini RS, Bergom C, Theberge V, El-Tamer M, Zellars RC, Shumway DA, Chen GP, Julian TB, Wolmark N. NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS \leq 18 breast cancer. *Journal of Clinical Oncology* 40[16_suppl], TPS613. 6-1-2022. Wolters Kluwer. 6-1-2022.
Keywords: BRE/MAC28
Notes: Recd fr HStanton; poster presentation at ASCO, June 3-7, 2022, Chicago IL; entered COShea 2022JUN09

